Meaning
nausea and vomiting
NASOPHARYNGEAL CARCINOMA
This randomized clinical trial found no difference between weekly and thrice-weekly fosaprepitant for the primary outcome of complete response.This pilot randomized clinical trial assesses the safety and efficacy of fosaprepitant weekly vs every 3 weeks for the prevention of nausea and vomiting caused by concurrent chemoradiotherapy among patients with nasopharyngeal carcinoma.